enalapril has been researched along with Hyperventilation* in 2 studies
1 trial(s) available for enalapril and Hyperventilation
| Article | Year |
|---|---|
Effect of angiotensin converting enzyme inhibition on airway conductance during hypocapnic hyperventilation in normal subjects.
In nine normal subjects, specific airway conductance was measured by whole body plethysmography before and immediately after hypocapnic hyperventilation. This procedure, forced expiratory manoeuvres and arterial blood pressure measurements were carried out before and 4 h after placebo and the angiotensin converting enzyme inhibitor, enalapril, in a double-blind, randomized study design. Bronchoconstriction to hypocapnic hyperventilation was shown by a reduction in specific airway conductance on all occasions (P < 0.001). A reduction in mean blood pressure was obtained after enalapril compared to placebo (P < 0.05). No significant change attributable to enalapril was observed in any lung function measurement either at rest or immediately after hypocapnic hyperventilation, despite an expected enhancement of endogenous angiotensin converting enzyme activity by alkalosis. Inhibition of angiotensin converting enzyme revealed no effect of the endogenous activity of this enzyme on airway calibre either at rest or during the bronchoconstrictor response to hypocapnic hyperventilation. Topics: Adolescent; Adult; Angiotensin-Converting Enzyme Inhibitors; Bronchoconstriction; Double-Blind Method; Enalapril; Humans; Hydrogen-Ion Concentration; Hyperventilation; Hypocapnia; Male | 1995 |
1 other study(ies) available for enalapril and Hyperventilation
| Article | Year |
|---|---|
[Efficacy of long-term enalapril use in combined therapy of chronic pulmonary heart].
86 patients with chronic obstructive pulmonary diseases (COPD) and tuberculosis in combination with COPD complicated by chronic pulmonary heart (CPH) received a 18-month continuous treatment with enalapril (enap, D. Reddis Laboratories). It was found that the addition of enap, an inhibitor of ACE, to combined therapy of CPH patients is pathogenetic as it results in lowering of blood pressure in pulmonary artery, remodeling of hypertrophic right ventricle of the heart and decline of left ventricular dysfunction, in improvement of functional state of the lungs, in arrest of progression of cardiac failure. Long-term administration of the drug induced no serious side effects and is well tolerated. Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Combined Modality Therapy; Cough; Enalapril; Humans; Hyperventilation; Middle Aged; Pulmonary Disease, Chronic Obstructive; Pulmonary Heart Disease; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary; Ventricular Remodeling | 2003 |